TSE:IMV - IMV Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$6.35 -0.04 (-0.63 %)
(As of 07/22/2018 06:10 AM ET)
Previous CloseC$6.35
Today's RangeC$6.33 - C$6.47
52-Week RangeC$3.33 - C$9.49
Volume24,700 shs
Average Volume41,116 shs
Market CapitalizationC$255.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.55
IMV logoIMV Inc., a clinical-stage company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is based in Halifax, Canada.

Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolTSE:IMV
CUSIPN/A
Phone+1-902-4921819

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares42,961,000
Market CapC$255.47

IMV (TSE:IMV) Frequently Asked Questions

What is IMV's stock symbol?

IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."

How were IMV's earnings last quarter?

Imv Inc (TSE:IMV) released its earnings results on Monday, May, 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.01. The company had revenue of $0.10 million for the quarter. View IMV's Earnings History.

When is IMV's next earnings date?

IMV is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for IMV.

What price target have analysts set for IMV?

2 analysts have issued 1 year price objectives for IMV's stock. Their predictions range from C$10.40 to C$12.00. On average, they anticipate IMV's share price to reach C$11.20 in the next twelve months. This suggests a possible upside of 76.4% from the stock's current price. View Analyst Ratings for IMV.

What is the consensus analysts' recommendation for IMV?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of IMV's key competitors?

Who are IMV's key executives?

IMV's management team includes the folowing people:
  • Mr. Frederic Ors, Pres, CEO & Director (Age 44)
  • Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICD, Chief Financial Officer (Age 53)
  • Dr. Gabriela Nicola Rosu M.D., Chief Medical Officer
  • Mr. Joseph Sullivan, Sr. VP of Bus. Devel.
  • Mr. Leeladhar Sammatur, VP of Process Devel. & Manufacturing

Has IMV been receiving favorable news coverage?

News headlines about IMV stock have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. IMV earned a news sentiment score of 0.17 on Accern's scale. They also gave news stories about the company an impact score of 45.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of IMV?

Shares of IMV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately C$6.35.

How big of a company is IMV?

IMV has a market capitalization of C$255.47 million.

How can I contact IMV?

IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.


MarketBeat Community Rating for IMV (TSE IMV)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  60
MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.